The University of Utah's Independent Student Voice

The Daily Utah Chronicle

The University of Utah's Independent Student Voice

The Daily Utah Chronicle

The University of Utah's Independent Student Voice

The Daily Utah Chronicle

Write for Us
Want your voice to be heard? Submit a letter to the editor, send us an op-ed pitch or check out our open positions for the chance to be published by the Daily Utah Chronicle.
@TheChrony
Print Issues
Write for Us
Want your voice to be heard? Submit a letter to the editor, send us an op-ed pitch or check out our open positions for the chance to be published by the Daily Utah Chronicle.
@TheChrony
Print Issues

Study could help fix eye conditions

By Deborah Rafferty

A new international study could eventually provide medications for diseases caused by leaky blood vessels, such as age-related macular degeneration and diabetes-related damage to the retina, known as retinopathy.

In the study led by Dean Li, professor of the internal medicine and director of molecular medicine program at the U School of Medicine, along with the University of California San Diego and the University of Bonn, Germany, researchers identified a drug-like compound that could strengthen the blood vessels to prevent leaking. The study was published Oct. 25 in Nature Cell Biology’s online edition and will be published in the journal in November.

“The central issue is these are major causes of significant blindness in developed countries,” Li said. “Essentially, our study is trying to understand how to keep blood vessels from leaking.”

In AMD and diabetic retinopathy, genetic defects do not directly affect the structure of the blood vessels in the eye, Li said. However, those genetic defects have been identified as the source of inflammation, which in turn cause the blood vessel to become weaker and leak. When the blood vessels in the eye leak, the retina becomes soggy, distorting the vision. With the possibility of a new drug, the effects from these diseases could be reversed, Li said.

The study focused on pathways in the eye that affect the stability of blood vessels. Researchers were able to manipulate certain genes related to the cause of weak blood vessels in mouse models. The drug-like compound they developed would be able to trick cells that receptors have activated, which leads to stronger vessels, Li said.

This drug would be easier to develop than manipulating the genes themselves and provides proof of concept that the process is understood well enough that it could be made into a drug for humans, Li said.

“There is the hope that we can do the same thing in humans,” Li said. “This opens up the possibility of new ways of making medicines that haven’t really been tried.”

Although this drug-like compound has worked in animals, it is far from ready to distribute to humans, Li said.

The National Institutes of Heath, Juvenile Diabetes Resource Fund, the Department of Defense, and the American Heart Association funded the research.

[email protected]

Leave a Comment

Comments (0)

The Daily Utah Chronicle welcomes comments from our community. However, the Daily Utah Chronicle reserves the right to accept or deny user comments. A comment may be denied or removed if any of its content meets one or more of the following criteria: obscenity, profanity, racism, sexism, or hateful content; threats or encouragement of violent or illegal behavior; excessively long, off-topic or repetitive content; the use of threatening language or personal attacks against Chronicle members; posts violating copyright or trademark law; and advertisement or promotion of products, services, entities or individuals. Users who habitually post comments that must be removed may be blocked from commenting. In the case of duplicate or near-identical comments by the same user, only the first submission will be accepted. This includes comments posted across multiple articles. You can read more about our comment policy at https://dailyutahchronicle.com/comment-faqs/.
All The Daily Utah Chronicle Picks Reader Picks Sort: Newest

Your email address will not be published. Required fields are marked *